Biosimilars Payments In Medicare: CMS Signals Willingness To Change
Executive Summary
Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.
You may also be interested in...
Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.
Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.
Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say
Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.